Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.

doi:10.1200/JCO.2021.39.15_suppl.6022

HFCAS OpenIR

	Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.
	Chi, Yihebali ; Gao, Ming ; Zhang, Yuan ; Shi, Feng ; Cheng, Ying ; Guo, Zhuming ; Ge, Minghua ; Qin, Jianwu ; Zhang, Jiewu ; Li, Zhendong ; Zhou, Xiaohong ; Huang, Rui ; Chen, Xiaohong ; Liu, Hui ; Cheng, Ruochuan ; Xu, Zhengang ; Zheng, Xiangqian ; Li, Dapeng ; Tang, Pingzhang
	2021-05-20
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.6022
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000708120603213
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126617
专题	中国科学院合肥物质科学研究院
作者单位	1.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China 2.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc,Tianjin Union Med Ctr, Tianjin, Peoples R China 3.Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Peoples R China 4.Hunan Canc Hosp, Changsha, Peoples R China 5.Jilin Canc Hosp, Changchun, Peoples R China 6.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China 7.Chinese Acad Sci, Zhejiang Prov Peoples Hosp, Peoples Hosp,Univ Chinese Acad Sci, Hangzhou Med Coll,ICBM,Canc Hosp,Zhejiang Canc Ho, Zhengzhou, Peoples R China 8.Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China 9.Harbin Med Univ Canc Hosp, Harbin, Peoples R China 10.China Med Univ, Tumor Hosp, Liaoning Tumor Hosp & Inst, Shenyang, Peoples R China 11.Chongqing Univ Canc Hosp, Chongqing Canc Hosp, Chongqing, Peoples R China 12.Sichuan Univ, West China Hosp, Chengdu, Peoples R China 13.Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China 14.Fujian Canc Hosp, Fuzhou, Peoples R China 15.Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China 16.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
推荐引用方式 GB/T 7714	Chi, Yihebali,Gao, Ming,Zhang, Yuan,et al. Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Chi, Yihebali.,Gao, Ming.,Zhang, Yuan.,Shi, Feng.,Cheng, Ying.,...&Tang, Pingzhang.(2021).Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Chi, Yihebali,et al."Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).